BamSEC and AlphaSense Join Forces
Learn More

Theravance Biopharma Inc. – Material Contracts

NASDAQ: TBPH    
Share price (5/21/26): $16.34    
Market cap (5/21/26): $842 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 5 pages February 8, 2026 ​ by Email ​ Dr. Aine Miller ​ Re:your Employment Contract Dated 10 February 2020 ​ Dear Dr. Miller I Refer to Your Contract of Employment Dated 10 February 2020 With Theravance Biopharma Ireland Limited (The “Company”). the Purpose of This Letter Is to Amend This Contract by the Addition of the Following Clause 28: 28. Severance Upon Termination Without Misconduct
12/34/56
EX-10.8
from 10-K 3 pages Theravance Biopharma, Inc. Amended and Restated 2013 Equity Incentive Plan (“The Plan”) ​ Irish Addendum
12/34/56
EX-10.19
from 10-K 14 pages Theravance Biopharma, Inc. Executive Severance Plan and Summary Plan Description ​
12/34/56
EX-10.3
from 10-Q 22 pages Employment Contract of Indefinite Duration
12/34/56
EX-10.2
from 10-Q 7 pages Separation Agreement and Release of Claims
12/34/56
EX-10.1
from 10-Q 4 pages Theravance Biopharma Inc. Amended and Restated 2013 Equity Incentive Plan Restricted Share Purchase Agreement
12/34/56
EX-10.39
from 10-K 3 pages June 12, 2018 Revised Offer Rhonda F. Farnum [Address] Dear Rhonda
12/34/56
EX-10.1
from 8-K 27 pages Cooperation Agreement
12/34/56
EX-10.3
from 10-Q 7 pages Theravance Biopharma, Inc. 2013 Equity Incentive Plan Notice of Restricted Share Unit Award
12/34/56
EX-10.2
from 10-Q 2 pages [Theravance Biopharma Company Logo] ​ June 16, 2014 ​ Aziz Sawaf ​ Dear Aziz: ​
12/34/56
EX-10.1
from 10-Q 5 pages ​ [Theravance Biopharma Company Logo] ​ May 12, 2014 ​ Brett Grimaud ​ Dear Brett: ​
12/34/56
EX-10.1
from 8-K 17 pages Amended and Restated 2013 Equity Incentive Plan Theravance Biopharma, Inc. 2013 Equity Incentive Plan (Originally Adopted Effective October 22, 2013, Amended & Restated Effective February 14, 2023) 1
12/34/56
EX-10.77
from 10-K 8 pages Separation Agreement and Release of Claims
12/34/56
EX-10.72
from 10-K 14 pages To the Members and the Board of Directors of Theravance Respiratory Company, LLC Opinion on the Financial Statements
12/34/56
EX-10.4
from 10-Q 2 pages First Amendment to the Theravance Biopharma, Inc. Change in Control Severance Plan ​
12/34/56
EX-10.2
from 8-K 8 pages Release Agreement
12/34/56
EX-10.1
from 8-K 43 pages Master Consent
12/34/56
EX-10.72
from 10-K 14 pages To the Members and the Board of Directors of Theravance Respiratory Company, LLC Opinion on the Financial Statements
12/34/56
EX-10.71
from 10-K 9 pages Settlement Agreement
12/34/56
EX-10.70
from 10-K 5 pages Consulting Agreement
12/34/56